Introduction
============

*Pseudomonas aeruginosa* is a major nosocomial pathogen, particularly dangerous to cystic fibrosis patients and populations having weak immune system. Moreover, this organism is resistant to many antibacterial drugs [@B1]. Several mechanisms for resistance against antibiotics have been proposed - which include antibiotic inactivation by enzymatic action, altering the efflux pump mechanisms, target mutation, and decreased uptake of antibiotics [@B2]. Due to the frequent development of resistance during monotherapy treatment of infected patients, multiple combinations of antibacterial agents are proposed [@B3]-[@B4]. Synergy is reported for β-lactams in combination with aminoglycoside antibiotics. However, the increasing resistance of *Pseudomonas sp.* to β-lactams and the toxicity concerns with the aminoglycosides limit the use of these combinations [@B5]. It is also reported that polymyxin B can be used in combination with other antimicrobials to treat multidrug resistant (MDR) gram-negative respiratory tract infections caused by several clinical strains of *P. aeruginosa* [@B6]. Also, fluoroquinolones in combination with potent anti-pseudomonal β-lactam agents are reported to prevent the development of resistance in *P. aeruginosa*[@B7]-[@B8]. Earlier, Marie *et al*. reported that cystic fibrosis patients infected with *P. aeruginosa* can be effectively treated with clarithromycin/tobramycin combination [@B9]. However, alarmingly numbers of *P. aeruginosa* strains are reported to show resistance to multiple antibiotics. Concomitantly, multidrug resistance and dual resistance are major issues in developing a definitive therapy for *P. aeruginosa* infections [@B10].

Since long, natural products are in use for the development of novel drugs to treat various bacterial infections. Several studies have proposed that natural compounds in combination with antibiotics are a new strategy for developing therapies for infections caused by bacterial species and that natural plant products can potentiate the activity of antibiotics in combination [@B10]-[@B13]. For example, secondary metabolites like essential oils, flavonols and alkaloids have been reported to have antimicrobial properties [@B14]-[@B18]. Also, Michael and colleagues reported that the use of bacterial resistance modifiers such as efflux pump inhibitors, derived from natural sources mainly from plants can suppress the emergence of MDR strains [@B19].

Phenolic compounds from medicinal herbs and dietary plants possess a range of bioactivities like - antibacterial, antifungal, antiviral, antimutagenic and anti-inflammatory activities. Moreover, extensive clinical evidence has shown that chemoprevention by phenolic phytochemicals is an inexpensive, readily applicable approach in the chemotherapy and management [@B20]. Here, we investigate the *in vitro*antimicrobial activities of 7 different antibiotics (ciprofloxacin, ceftazidime, tetracycline, trimethoprim, sulfamethoxazole, polymyxin B and piperacillin) in combination with 6 phytochemicals (protocatechuic acid, gallic acid, ellagic acid, rutin, berberine and myricetin) against 5 strains of *P. aeruginosa*using minimum inhibitory concentrations (MIC), checkerboard test, and time-kill assay. All antibiotics under investigation have earlier been reported as anti-pseudomonal drugs and have been reported to have different mechanisms of action (have different targets). The results of our analysis with data on antibiotic-phytochemical interaction network are presented.

Materials and Methods
=====================

Antimicrobial agents
--------------------

Standard powders of antibiotics and phytochemicals listed in Table [1](#T1){ref-type="table"} were obtained from Sigma - Aldrich, Singapore. Stock solutions were prepared and diluted according to Clinical and Laboratory Standards Institute (CLSI) standards and manufacturer\'s recommendations and stored at -20°C.

Bacterial isolates
------------------

Five *P. aeruginosa*strains were used in this study including two clinical isolates (DB5218, DR3062) which was obtained from Singapore General Hospital, Singapore. The other three strains were *P. aeruginosa* ATCC 15692 (American Type Culture Collection, Manassas, USA), *P. aeruginosa* PA01 (University of Geneva, Switzerland), *P. aeruginosa* PT121 (University of Geneva, Switzerland). Before use, bacterial suspension was made from fresh culture and stored at -80⁰C using 30% glycerol.

Antimicrobial susceptibility testing
------------------------------------

MIC is defined as the lowest concentration of the antimicrobial agent that inhibits the bacterial growth as detected by lack of visual turbidity. Broth microdilution method was used to determine the MICs for 7 antibiotics and 6 phytochemicals according to Clinical and Laboratory Standards Institute guidelines [@B21]. The medium used for the broth microdilution test was Iso-sensitest Broth (ISB). For each strain of *P. aeruginosa*, three to five colonies were transferred from overnight growth plate into 5 ml of ISB to approximate the density of 0.5 McFarland standard and incubated at 35⁰C for 2-3 h. This suspension with the inoculum concentration of 10^8^colony forming units (CFU/ml) was then diluted to 10^6^CFU/ml with the Iso-sensitest broth. Serial two-fold dilutions of all the antimicrobial agents with the following concentrations (µg/ml): ciprofloxacin (0.06 - 32), ceftazidime (0.25 - 32), trimethoprim (4 - 128), sulfamethoxazole (8 - 512), tetracycline (4 - 128), polymyxinpolymyxin B (0.25 - 32), piperacillin (0.25 - 32), protocatechuic acid (250 - 8000), ellagic acid (1000 - 16000), gallic acid (250- 8000), rutin (1000 - 16000), berberine (1000-16000), myricetin (100 - 1000) were prepared with ISB and placed in 96-well microtiter plates and the lowest concentration inhibiting visible growth after 18-20 h at 35⁰C was recorded as MIC.

Checkerboard assay
------------------

The activity of phytochemicals and antibiotics in combination was investigated using the checkerboard broth microdilution method. Two fold serial dilutions of the antibiotic and two fold serial dilutions of the phytochemicals were prepared for every combination tested and 50 µl aliquots of each component was placed into the wells of the sterile 96-well microtiter plate. The inoculum was prepared using the above described MIC determination method. The microtiter plates were then incubated at 35⁰C and MIC was determined after 18-20 h of incubation.

The Fractional inhibitory concentration (FIC index) for all the combinations was determined using the following formula,
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FIC~A~, FIC~B~ - Fractional inhibitory concentration of drug A & B respectively. MIC~A~, MIC~B~ - Minimum inhibitory concentration of drug A & B respectively.

\[A\], \[B\] - Concentration of drug A & B respectively.

FIC index by checkerboard method is interpreted as follows: ≤ 0.5- synergy; \> 0.5 and ≤ 4- additivity; and \> 4 - antagonism.

The effects of sub-inhibitory concentrations of test compounds individually and in combination on PA01 growth were also evaluated by measuring the growth rates after 20 h of incubation at 35⁰C in microtitre plates and OD~600~was measured.

Time-kill assay
---------------

Time-kill assays were performed using the identified synergistic combinations (SMX plus PA, SMX plus EA, SMX plus GA and TET plus GA) against a single bacterial isolate (ATCC 15692). Individual colonies were isolated from the overnight growth plate and suspended in sterile ISB to approximate the density of 0.5 McFarland standard. The suspension was diluted 1:10 in ISB to obtain a standard inoculum of 1 x 10^6^CFU/ml. 100 µl of the diluted suspension was added to 0.9 ml of ISB. Double dilutions for each antibiotic and phytochemicals were prepared. Tubes containing individual drugs and the combination were incubated at 35°C for 24 h. From each tube 100 µl of sample was removed at 0, 4, 8 and 24 h, respectively and plated to count the viable cells. Growth control and sterility control were included for each assay. The killing rate was determined by plotting viable colony counts (CFU/ml) against time. Synergy was defined as a ≥2 log~10~ CFU/ml decrease of viable count by the combination compared with the most active single agent.

Statistical analysis
--------------------

The dose response values and time-kill data are presented as mean ± SD (Standard deviation). The analysis was performed in triplicate.

Results
=======

Antimicrobial susceptibility testing
------------------------------------

This study explored the antimicrobial activities of the phytochemicals alone and in combination with 7 anti-pseudomonal drugs (antibiotics) against 5 strains of *P. aeruginosa* (including 2 clinical strains). All the 5 strains of *P. aeruginosa*were susceptible to the anti-pseudomonal drugs chosen for investigation *i.e.* ciprofloxacin, ceftazidime, trimethoprim, sulfamethoxazole, tetracycline, polymyxin B and piperacillin. MIC value was found to be highest for sulfamethoxazole (128µg/ml) and lowest for ciprofloxacin (0.125µg/ml) among the antibiotics (Table [2](#T2){ref-type="table"}).

The phytochemicals used in this study significantly inhibited the growth of all the bacterial strains under investigation. Among the phytochemicals tested, myricetin (500µg/ml), protocatechuic acid (2000µg/ml) and gallic acid (2000µg/ml) showed lower MIC than ellagic acid (4000µg/ml), rutin (4000µg/ml) and berberine (4000µg/ml). The minimum inhibitory concentrations of the phytochemicals are listed in Table [2](#T2){ref-type="table"}.

Combination of phytochemicals and antibiotics against P. aeruginosa
-------------------------------------------------------------------

The combination effects of anti-pseudomonal drugs and phytochemicals are summarized in Table [3](#T3){ref-type="table"}.

Our results show that the combinations of sulfamethoxazole plus protocatechuic acid, sulfamethoxazole plus ellagic acid and sulfamethoxazole plus gallic acid have synergistic mode of interactions for all the strains of *P. aeruginosa* under investigation. It was also observed that the antifolate drug, sulfamethoxazole is synergistic with myricetin in three strains (PA01, DB5218 and DR3062) and additive for two strains (ATCC and PT121) of *P. aeruginosa*. Also, tetracycline in combination with gallic acid demonstrates synergy for all the isolates under investigation. Other antimicrobials - ciprofloxacin, ceftazidime, trimethoprim, polymyxin B and piperacillin show additivity in combination with phytochemicals, for all the strains under investigation. It is noteworthy, that none of the antibiotic -phytochemical combinations show antagonism.

The FIC indices of the combinations sulfamethoxazole plus protocatechuic acid and sulfamethoxazole plus ellagic acid range from 0.25 - 0.5, showing significant synergistic activity for all the strains under investigation (Table [3](#T3){ref-type="table"}).

The growth inhibitory properties of all the test compounds and additive combinations assayed over 20 h period in microtiter wells at sub-inhibitory concentration was similar to the growth control well (no antimicrobials). Moreover, the synergistic combinations were found to inhibit the test strain (PA01) growth at similar concentrations (Figure [1](#F1){ref-type="fig"}). The drug interaction data between various classes of antibiotics and phytochemicals is represented as a figure to provide some insights on their mechanism of action (Figure [2](#F2){ref-type="fig"}).

Time-kill curves
----------------

Time-kill assays for the most potent synergistic combinations (sulfamethoxazole plus protocatechuic acid, sulfamethoxazole plus ellagic acid, sulfamethoxazole plus gallic acid and tetracycline plus gallic acid) on ATCC strain are shown (Figures [3](#F3){ref-type="fig"}: A-D). The net reduction in colony count was seen consistently (throughout 24 h) at (1/2^th^+ 1/2^th^) x MIC for the identified synergistic drug-herb combinations. Any single active agent alone at 1/2^th^ x MIC did not show significant inhibition of the isolates tested. The rate of killing was higher at 8 h with maximum reduction in the colony count at 24 h. When 1/2^th^ x MIC sulfamethoxazole was combined with 1/2^th^ x MIC protocatechuic acid, 1/2^th^ x MIC sulfamethoxazole was combined with 1/2^th^ x MIC gallic acid, 1/2^th^ x MIC tetracycline was combined with 1/2^th^ x MIC gallic acid, significant decrease in bacterial count was observed between 8 - 24 h with maximum reduction in the growth baseline by 4 - 5 log~10~ CFU/ml. However, when 1/2^th^ x MIC sulfamethoxazole was combined with 1/2^th^ x MIC ellagic acid a reduction of 1 - 2 log~10~decrease in viable count occurred at 24 h.

Discussion
==========

*P. aeruginosa*is a tenacious pathogen because of its ability to develop resistance to multiple antibiotics. Though, there are a few anti-pseudomonal drugs in the pipeline [@B22], there is an urgent need for novel and effective infection control strategy to face this highly critical therapeutic challenge of drug resistance [@B23]-[@B24].

Since long, bioactive compounds from natural sources have shown the potential to inhibit resistance mechanisms [@B25]. Here, we report on the synergistic and additive interactions between selected phytochemicals and antibiotics which are folate biosynthesis inhibitors, DNA/protein synthesis inhibitors, and cell permeability/cell wall inhibitors.

Antibiotics and phytochemicals - interaction analysis
-----------------------------------------------------

### Folate Biosynthesis inhibitors

Sulfamethoxazole (a sulfonamide), competitively inhibits the binding of para aminobenzoic acid (*p*ABA) to the enzyme dihydropteroate synthase (DHPS) that catalyses the formation of dihydrofolate [@B26]. Trimethoprim inhibits dihydrofolate reductase (DHFR) enzyme which catalyses the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate, an important cofactor involved in supplying one carbon for the synthesis of purines, pyrimidines, methionine and many other amino acids. It must be mentioned that nearly all prokaryotes must synthesize folate compounds *de novo*, starting with GTP and utilizing several different enzymes in a multi-step pathway, whereas eukaryotes (including human) are able to utilize the dietary folates by uptake through a carrier-mediated transport system [@B27]. Hence, DHFR and DHPS are good targets for antifolates [@B28].

Recently, we proposed that phytochemicals (protocatechuic acid, gallic acid, quercetin and myricetin) possibly bind to *P. aeruginosa* DHFR and in combination with sulfamethoxazole may inhibit different steps in the same pathway, thereby resulting in synergistic mode of action. On the other hand indifferent/additive interaction of trimethoprim and phytochemicals may be due to the binding of these phytochemicals into the active site cavity of DHFR, thereby resulting in interactions with common target residues similar to that of trimethoprim, leading to competitive inhibition and no inhibition of cell growth [@B29]. Here, we reconfirm the above findings using 5 strains - including two clinical strains- of *P. aerugoinosa* and also provide data on MICs, and time-kill. We further report on synergism between the combination of ellagic acid and sulfamethoxazole and propose similar mode of action, as ellagic acid may also potentially bind in *P. aeruginosa* DHFR active site.However, combinations of sulfamethoxazole plus rutin, sulfamethoxazole plus berberine, trimethoprim plus rutin and trimethoprim plus berberine resulted in indifferent/additive mode of interaction.

### Protein synthesis (30S ribosome) inhibitor

Synergistic interactions were observed for combination of tetracycline and gallic acid for all the *P. aeruginosa*strains under investigation. Sudano *et al*., reported that epigallocatechin gallate enhances the tetracycline activity for resistant staphylococcal isolates by impairment of tetracycline efflux pump activity and increased intracellular retention of the drug leading to synergistic drug combination [@B30]. Since, gallic acid is a structural component of epigallocatechin galate, there is a possibility that it may behave similarly in combination with tetracycline. Additive mode of interactions was observed for combinations of tetracycline and protocatechuic acid, ellagic acid, rutin, berberine and myricetin for all the *P. aeruginosa*strains under investigation.

### DNA replication inhibitor

The combinations of ciprofloxacin/phytochemicals were found to be additive. Ciprofloxacin has been earlier reported to have two targets (DNA gyrase and DNA topoisomerase IV) [@B31]. It is suggested that quercetin, inhibits supercoiling activity of *E. coli* bacterial gyrase by binding to the ATP binding site of gyrase B [@B32]. It is also reported that quercetin and myricetin bind to DNA and induce enzymic DNA breakage [@B33]. Recently, epigallocatechin gallate is reported to inhibit *E. coli* bacterial DNA gyrase [@B34]. Bernard *et al.* found that rutin induces topoisomerase IV-mediated DNA cleavage and growth inhibition in *E. coli* [@B35]. The mechanism of action of berberine was found to be similar to that of rifampicin and norfloxacin possibly targeting RNA polymerase, DNA gyrase and topoisomerase IV enzymes [@B36]. The present study interaction data from (Figure [2](#F2){ref-type="fig"}) shows similar mechanism of action of the above phytochemicals as DNA synthesis inhibitors by having indifferent activity in combination with ciprofloxacin.

### Cell wall / cell membrane permeability inhibitors

Ceftazidime, causes cell lysis in *P. aeruginosa*due to its primary activity against membrane proteins to which penicillin is reported to bind [@B37]. Also, quercetin is reported to cause increase in permeability of the inner bacterial membrane and loss of membrane potential [@B38]. On the other hand, galangin, a structural analogue of quercetin, induces cytoplasmic membrane interference damage and potassium leakage leading to cell wall damage [@B39]. The correlation between indifferent activities of phytochemicals in combination with ceftazidime from the experimental data may possibly suggest that these compounds may act at same target either at different sites in the cytoplasmic membrane with direct contact with agonist site or at the same site.

Polymyxin B is reported to have a detergent like mechanism of action and interacts with lipoplysaccharide (LPS) of the outer membrane of *P. aeruginosa* [@B40]-[@B41]. Polymyxin B in combination with the tested phytochemicals results in additive/indifferent mode of interaction. The LPS molecules in the outer leaflet form specific contacts with integral outer membrane proteins and are required for LPS transport to the bacterial cell surface [@B42]. It is earlier suggested that in the presence of lipopolysaccharide as a barrier in gram-negative bacteria, the susceptibility of catechins may be low [@B43]. The combinations of polymyxin B plus phytochemicals may help overcome this barrier due to the detergent like activity of polymyxin B and cytoplasmic membrane damage inducing ability of phytochemicals. However, it is possible that there may be a direct competition for binding to LPS or by indirectly affecting the same site of the same target by overlapping actions subsequently resulting in additive mode of action. Similarly, piperacillin, an extened spectrum β-lactam antibiotic shows additive effect in combination with the phytochemicals under investigation.

This study highlights the various systemic interaction patterns and may help identify new drug combinations with novel mechanism of action. It must be noted that no antagonistic interaction was observed for any antibiotic- phytochemical combination studied. These results suggest that the identified combinations could be potential and effective strategy, without the concern of antagonistic interactions. One of the major concerns for the dietary phytochemicals under investigation is the higher MIC values in comparison to antibiotics, which are generally in the range of \< 10 µg/ml range [@B44]. However, it is noteworthy that, the main polyphenol dietary sources are fruits and beverages with an average total intake of 1g/day and after the consumption of 10-100 mg of a single phenolic compound, the maximum concentration in plasma rarely exceeds 1 µM [@B45]. Additionally the toxicity of these phytochemicals are very low and as of date, very few adverse side effects are reported [@B46]. Nonetheless, detailed analysis needs to be carried out to characterize the interactions of antibacterial phytochemicals and antibiotics with the use of different approaches and methods facilitated by targets profile and toxicity data.

Conclusion
==========

The present study clearly highlights the low toxic potential of phytochemicals as antibacterial compounds and suggest on the possibility of use of the above shown synergistic drug-herb combinations for combating infections caused by this pathogen. The drug-herb network presented in this study shows the level of interactions between various classes of antibiotics and phytochemicals and provides a baseline to identify the potential mechanism of action of these potential phytochemicals. Moreover, phytochemicals are reported to have the capability of increasing the susceptibility of the pathogen to various drugs and also reduce the toxicity of the drugs when used in combination. Finally, the experimental findings encourage further studies with these agents and other antimicrobial classes and *in vivo* animal experiments to validate these interesting observations before clinical test can move forward. The investigations are underway to further characterize the interaction of the above phytochemicals and antibiotics.
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![PA01 growth in subminimum inhibitory concentrations of individual antibiotics and phytochemicals and their combination. Dose response and classification of interactions for antibiotics and phytochemicals used in this study. Each panel consists of bars representing measured growth rates (OD~600\ nm~) after 24 hr incubation with sub-inhibitory concentration of the antimicrobials, from left to right: growth control (no antibiotics), antibiotics alone (1/4 x MIC), phytochemicals alone (1/4 x MIC), antibiotics + phytochemicals (1/4 + 1/4 x MIC). The background colour represents the type of interactions, red - additive/indifferent, green - synergistic.](ijbsv06p0556g03){#F1}

![Network interactions between antibiotics and phytochemicals. Antibiotics are classified based on their respective targets and mechanism of action. CE, ceftazidime; PI, piperacillin - cell wall inhibitors; T, trimethoprim; S, sulfamethoxazole - folic acid biosynthesis inhibitors; POL B, polymyxin B - cell membrane inhibitors; TET, tetracycline - 30S ribosome inhibitors; CIP, ciprofloxacin - DNA gyrase and toposiomerase IV inhibitors. Phytochemicals are classified based on their classes. PA, protocatechuic acid; GA, gallic acid; EA, ellagic acid -polyphenol antioxidants (phenolic acids); BER, berberine - alkaloid; RUT, rutin; MYR, myricetin - flavonoids.](ijbsv06p0556g04){#F2}

###### 

Time-kill data for synergistic combinations at ½ x MIC against *P. aeruginosa*ATCC strain 15692. (A) Combinations of sulfamethoxazole (SMX) and protocatechuic acid (PA); (B) Combinations of sulfamethoxazole (SMX) and gallic acid (GA); (C) Combinations of sulfamethoxazole (SMX) and ellagic acid (EA); (D) Combinations of tetracycline (TET) and gallic acid (GA). Filled diamond, control; Filled square, antibiotics; Filled triangle, phytochemicals; Filled circle, antibiotic and phytochemical combination.
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List of antibiotics and phytochemicals used in this study
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###### 

Antimicrobial activity (MIC values) of all the antibiotics and phytochemicals against five strains of *P. aeruginosa*

  Antimicrobials        Minimum inhibitory concentration (µg/ml)                           
  --------------------- ------------------------------------------ ------- ------- ------- ------
  Ciprofloxacin         0.125                                      0.125   0.125   0.125   0.25
  Ceftazidime           2                                          2       2       4       8
  Trimethoprim          32                                         32      32      32      32
  Sulfamethoxazole      128                                        128     128     128     128
  Tetracycline          32                                         32      32      32      32
  Polymyxin B           2                                          2       2       2       2
  Piperacillin          2                                          2       2       2       16
  Protocatechuic acid   2000                                       2000    2000    2000    2000
  Ellagic acid          4000                                       4000    4000    4000    4000
  Gallic acid           2000                                       2000    2000    2000    2000
  Rutin                 4000                                       4000    4000    4000    4000
  Berberine             4000                                       4000    4000    4000    4000
  Myricetin             500                                        500     500     500     500

###### 

*In vitro* activity of all antimicrobial combinations against five strains of *P. aeruginosa.*The values show the FIC index.

  Antibiotics + Phytochemicals Combination   *P. aeruginosa* strains                                 
  ------------------------------------------ ------------------------- --------- --------- --------- ---------
                                                                                                     
  CIP+PA                                     2(I)                      2(I)      2(I)      2(I)      1(I)
  CIP+EA                                     2(I)                      2(I)      2(I)      2(I)      1(I)
  CIP+GA                                     2(I)                      2(I)      2(I)      2(I)      1(I)
  CIP+RUT                                    1(I)                      1(I)      1(I)      1(I)      1(I)
  CIP+BER                                    2(I)                      2(I)      2(I)      2(I)      1(I)
  CIP+MYR                                    2(I)                      2(I)      2(I)      2(I)      2(I)
                                                                                                     
  CF+PA                                      1(I)                      1(I)      1(I)      1(I)      1(I)
  CF+EA                                      1(I)                      1(I)      1(I)      2(I)      1(I)
  CF+GA                                      1(I)                      1(I)      1(I)      2(I)      1(I)
  CF+RUT                                     1(I)                      1(I)      1(I)      1(I)      2(I)
  CF+BER                                     1(I)                      1(I)      1(I)      1(I)      2(I)
  CF+MYR                                     1(I)                      1(I)      1(I)      1(I)      2(I)
                                                                                                     
  TMP+PA                                     1(I)                      1(I)      1(I)      1(I)      1(I)
  TMP +EA                                    1(I)                      1(I)      1(I)      1(I)      1(I)
  TMP +GA                                    1(I)                      1(I)      1(I)      1(I)      1(I)
  TMP +RUT                                   2(I)                      2(I)      2(I)      2(I)      2(I)
  TMP +BER                                   2(I)                      2(I)      2(I)      2(I)      2(I)
  TMP +MYR                                   2(I)                      2(I)      2(I)      2(I)      2(I)
                                                                                                     
  SMX+PA                                     0.5(S)                    0.25(S)   0.25(S)   0.25(S)   0.25(S)
  SMX +EA                                    0.5(S)                    0.25(S)   0.25(S)   0.25(S)   0.25(S)
  SMX +GA                                    0.5(S)                    0.5(S)    0.5(S)    0.5(S)    0.5(S)
  SMX +RUT                                   1(I)                      1(I)      1(I)      1(I)      1(I)
  SMX +BER                                   1(I)                      1(I)      1(I)      1(I)      1(I)
  SMX +MYR                                   1(I)                      0.5(S)    1(I)      0.5(S)    0.5(S)
                                                                                                     
  TET+PA                                     1(I)                      1(I)      1(I)      1(I)      1(I)
  TET +EA                                    1(I)                      1(I)      1(I)      1(I)      1(I)
  TET +GA                                    0.5(S)                    0.5(S)    0.5(S)    0.5(S)    0.5(S)
  TET +RUT                                   1(I)                      1(I)      1(I)      1(I)      1(I)
  TET +BER                                   1(I)                      1(I)      1(I)      1(I)      1(I)
  TET +MYR                                   1(I)                      1(I)      1(I)      1(I)      1(I)
                                                                                                     
  POL B+PA                                   2(I)                      2(I)      2(I)      2(I)      2(I)
  POL B +EA                                  2(I)                      2(I)      2(I)      2(I)      2(I)
  POL B +GA                                  2(I)                      2(I)      2(I)      2(I)      2(I)
  POL B +RUT                                 2(I)                      2(I)      2(I)      2(I)      2(I)
  POL B +BER                                 2(I)                      2(I)      2(I)      2(I)      2(I)
  POL B +MYR                                 4(I)                      4(I)      4(I)      4(I)      4(I)
                                                                                                     
  PIP+PA                                     1(I)                      1(I)      1(I)      1(I)      1(I)
  PIP+EA                                     2(I)                      2(I)      2(I)      2(I)      1(I)
  PIP+GA                                     1(I)                      1(I)      1(I)      1(I)      1(I)
  PIP+RUT                                    2(I)                      2(I)      2(I)      2(I)      2(I)
  PIP+BER                                    1(I)                      1(I)      1(I)      1(I)      2(I)
  PIP+MYR                                    2(I)                      2(I)      2(I)      2(I)      4(I)

S = Synergistic; I = Additivity/Indifferent.
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